Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 4/2016

01-10-2016 | Original Article

Association between IL-6 Gene (−174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk

Authors: Hai-ying Wang, Jin-jun Zhang, Xiang-yu Zheng, Jian-hua Liu, Yong-wei Li

Published in: Pathology & Oncology Research | Issue 4/2016

Login to get access

Abstract

We aimed to evaluate the association of IL-6 gene polymorphisms at positions of −174 and −572 and predisposition of endometrial adenocarcinoma (EAC) in a Chinese population. EAC patients have remarkably higher frequency of IL-6 -174 CC genotype [odds ratio (OR) =1.56, 95 % confidence interval (CI) =1.07–2.23; P = 0.03], IL-6 -572 CC genotype (OR =1.93, 95%CI =1.17–3.15; P = 0.01) and IL-6 -174 C allele (OR =1.22, 95 % CI =1.03–1.46; P = 0.04) compared with healthy controls. When stratified with FIGO stage, patients with III-IV EAC have a significantly higher frequency of IL-6 -174 CC genotype (OR =1.66, 95% CI =1.06–2.58; P = 0.02) than healthy controls. The CC genotype of IL-6 gene polymorphisms at positions of −174 and −572 may denote potential high risk of EAC.
Literature
1.
Fowler W, Mutch D (2008) Management of endometrial cancer. Women's Health (Lond Engl) 4:479–489CrossRef
2.
Hosoi A, Ueda Y, Shindo M, et al. (2013) Endometrial thickness measured by ultrasonography in postmenopausal patients with endometrial carcinoma has significance, irrespective of histological subtype. Int J Gynecol Cancer 23:1266–1269CrossRefPubMed
3.
Tao QS, Huang HL, Chai Y, et al. (2012) Interleukin-6 up-regulates the expression of interleukin-15 is associated with MAPKs and PI3-K signaling pathways in the human keratinocyte cell line, HaCaT. Mol Biol Rep 39:4201–4205CrossRefPubMed
4.
Bowcock AM, Kidd JR, Lathrop GM, et al. (1988) The human "interferon-beta 2/hepatocyte stimulating factor/interleukin-6" gene: DNA polymorphism studies and localization to chromosome 7p21. Genomics 3:8–16CrossRefPubMed
5.
Huang D, Zheng C, Giscombe R, Matell G, Pirskanen R, Lefvert AK (1999) Polymorphisms at −174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis. J Neuroimmunol 101:197–200CrossRefPubMed
6.
Bennermo M, Held C, Green F, et al. (2004) Prognostic value of plasma interleukin-6 concentrations and the −174 G > C and −572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysis. Atherosclerosis 174:157–163CrossRefPubMed
7.
Magalhães JF, Cortinhas AJ, Albuquerque CM, et al. (2013) Interleukin-6 gene -174G > C and -636G > C promoter polymorphisms and prostate cancer risk. Mol Biol Rep 40:449–455CrossRefPubMed
8.
Xu B, Niu XB, Wang ZD, et al. (2011) IL-6-174G > C polymorphism and cancer risk: a meta-analysis involving 29, 377 cases and 37, 739 controls. Mol Biol Rep 38:2589–2596CrossRefPubMed
9.
Garg R, Wollan M, Galic V, et al. (2006) Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol 103:793–796CrossRefPubMedPubMedCentral
10.
Nogueira de Souza NC, Brenna SM, Campos F, Syrjanen KJ, Baracat EC, Silva ID (2006) Interleukin-6 polymorphisms and the risk of cervical cancer. Int J Gynecol Cancer 16:1278–1282CrossRefPubMed
11.
Godarzi EM, Sarvestani EK, Aflaki E, Amirghofran Z (2011) Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus[J]. Clin Rheumatol 30(2):179–184CrossRefPubMed
12.
Prayong P, Mairiang E, Pairojkul C, et al. (2014) An interleukin-6 receptor polymorphism is associated with opisthorchiasis-linked cholangiocarcinoma risk in Thailand. Asian Pac J Cancer Prev 15:5443–5447CrossRefPubMed
13.
Liu Z, Wang Z, Xiao Y, Lu Y, Lu Y (2015) Association between the interleukin-6 gene polymorphisms and renal cancer risk. Immunol Lett 164:125–128CrossRefPubMed
14.
Ebadi N, Jahed M, Mivehchi M, Majidizadeh T, Asgary M, Hosseini SA (2014) Interleukin-12 and interleukin-6 gene polymorphisms and risk of bladder cancer in the Iranian population. Asian Pac J Cancer Prev 15:7869–7873CrossRefPubMed
15.
Totaro F, Cimmino F, Pignataro P, et al. (2013) Impact of interleukin-6-174 G > C gene promoter polymorphism on neuroblastoma. PLoS One 8:e76810CrossRefPubMedPubMedCentral
16.
Pohjanen VM, Koivurova OP, Mäkinen JM, et al. (2013) Interleukin 6 gene polymorphism −174 is associated with the diffuse type gastric carcinoma. Genes Chromosom Cancer 52:976–982CrossRefPubMed
17.
Tang S, Yuan Y, He Y, et al. (2014) Genetic polymorphism of interleukin-6 influences susceptibility to HBV-related hepatocellular carcinoma in a male Chinese Han population. Hum Immunol 75:297–301CrossRefPubMed
18.
Delahanty RJ, Xiang YB, Spurdle A, et al. (2013) Polymorphisms in inflammation pathway genes and endometrial cancer risk. Cancer Epidemiol Biomark Prev 22:216–223CrossRef
19.
Srivani R, Nagarajan B (2003) A prognostic insight on in vivo expression of interleukin-6 in uterine cervical cancer. Int J Gynecol Cancer 13:331–339CrossRefPubMed
20.
Bellone S, Watts K, Cane’ S et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol 2005; 98: 92–98.
21.
Wei LH, Kuo ML, Chen CA, et al. (2001) The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of mcl-1 through a PI 3-K/Akt pathway. Oncogene 20:5799–5809CrossRefPubMed
22.
Grimm C, Watrowski R, Baumühlner K, et al. (2011) Genetic variations of interleukin-1 and −6 genes and risk of cervical intraepithelial neoplasia. Gynecol Oncol 121:537–541CrossRefPubMed
Metadata
Title
Association between IL-6 Gene (−174 & -572 G/C) Polymorphisms and Endometrial Adenocarcinoma Risk
Authors
Hai-ying Wang
Jin-jun Zhang
Xiang-yu Zheng
Jian-hua Liu
Yong-wei Li
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 4/2016
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-016-0073-6

Other articles of this Issue 4/2016

Pathology & Oncology Research 4/2016 Go to the issue

Original Article

Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma

Review

Relevance of the Measles Virus Expression in Cancer - an Update

Original Article

Effective Targeting Survivin, Caspase-3 and MicroRNA-16-1 Expression by Methyl-3-pentyl-6-methoxyprodigiosene Triggers Apoptosis in Colorectal Cancer Stem-Like Cells

Original Article

Autophagy and Apoptosis Play Opposing Roles in Overall Survival of Esophageal Squamous Cell Carcinoma

Letter to the Editor

Frameshift Mutation of MED25, a Transcription Regulator, and its Mutational Heterogeneity in Colorectal Cancers

Short Communication

The Uncontrolled Sialylation is Related to Chemoresistant Metastatic Breast Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits